Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
University of Chicago
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
NeoImmuneTech
Royal Marsden NHS Foundation Trust
Eli Lilly and Company
Institut du Cancer de Montpellier - Val d'Aurelle
Aragon Pharmaceuticals, Inc.
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
BeOne Medicines
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medical University of South Carolina
Royal Marsden NHS Foundation Trust
University of Michigan Rogel Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Alabama at Birmingham
University of Maryland, Baltimore
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Cytovation AS
Big Ten Cancer Research Consortium
Big Ten Cancer Research Consortium
Bristol-Myers Squibb
Hope Biosciences Research Foundation
Institut Bergonié
Exelixis
Aileron Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Masonic Cancer Center, University of Minnesota
Bristol-Myers Squibb
Seagen Inc.
Acerta Pharma BV
Takeda
National Taiwan University Hospital
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Cytovation AS
NantCell, Inc.
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
University of Washington
Bristol-Myers Squibb
University of California, San Diego
Hoffmann-La Roche
University of Washington
Alaunos Therapeutics